EUROPEAN UNION

INTRA

Part I: Description of consignment

I.1. Consignor
Name
Address
Country ISO Code

I.2. IMSOC reference

I.2.a. Local reference

I.3. Central Competent Authority

I.4. Local Competent Authority

I.5. Consignee
Name
Address
Country ISO Code

I.6. Operator conducting assembly operations independently of an establishment
Name
Address
Approval Number
Country ISO Code

I.7. Country of origin ISO Code

I.8. Region of origin Code

I.9. Country of destination ISO Code

I.10. Region of destination Code

I.11. Place of dispatch
Name
Address
Approval Number
Country ISO Code

I.12. Place of destination
Name
Address
Approval Number
Country ISO Code

I.13. Place of loading
Name
Address
Approval Number
Country ISO Code

I.14. Date and time of departure

I.15. Means of Transport

Mode	International transport document	Identification

I.16. Transporter
Name
Address
Approval Number
Country ISO Code

I.17. Accompanying documents
Document Type
Accompanying document reference
Date of Issue
Country
Place of issue

I.18. Transport conditions
Chilled ☐ Ambient ☐ Frozen ☐

I.19. Container No / Seal No

I.20. Certified as
Germinal products ☐

I.21. For transit through a third country ☐
Third country ISO Code
Exit point BCP code
Entry point BCP code

I.22. For transit through Member State(s) ☐
Member State ISO Code

I.23. For export ☐
Third country ISO Code
Exit point BCP code

I.24. Estimated journey time

I.25. Journey Log

I.26. Total number of packages	I.27. Total quantity	I.28. Total gross weight

I.30. Description of consignment

1. 05 PRODUCTS OF ANIMAL ORIGIN, NOT ELSEWHERE SPECIFIED OR INCLUDED

0511 Animal products not elsewhere specified or included; dead animals of Chapter 1 or 3, unfit for human consumption

051199 Other

05119985 Other

Part I: Description of consignment

#1.	Commodity	Identification Number	Quantity	Nature of commodity	Identification Mark
Species		Package count	Date of collection / production	Plant / Establishment / Centre	Type

Part II: Certification

II. Health information

I, the undersigned official veterinarian, hereby certify that:

(1) ☐ [II.1. The ☐ [oocytes] (1) ☐ [in vivo derived embryos] (1) of ☐ [ovine] (1) ☐ [caprine] (1) animals described in Part I have been collected, processed and stored, and dispatched by the embryo collection team (2) which:

II.1.1. is approved and kept in a register by the competent authority;

II.1.2. complies with requirements as regards responsibilities, operational procedures, facilities and equipment set out in Part 2 of Annex I to Commission Delegated Regulation (EU) 2020/686;

(1) ☐ [II.1. The ☐ [oocytes] (1) ☐ [in vitro produced embryos] (1) ☐ [micromanipulated embryos] (1) of ☐ [ovine] (1) ☐ [caprine] (1) animals described in Part I have been collected or produced, processed and stored, and dispatched by the embryo production team (2) which:

II.1.1. is approved and kept in a register by the competent authority;

II.1.2. complies with requirements as regards responsibilities, operational procedures, facilities and equipment set out in Parts 2 and 3 of Annex I to Delegated Regulation (EU) 2020/686.]

II.2. The consignment consists of embryos of the ovine or caprine species which comply with the following conditions as regards classical scrapie:

(1) ○ either [they were collected from animals which have been kept continuously since birth on a holding or holdings recognised as having a negligible or a controlled risk of classical scrapie in accordance with Chapter A, Section A, point 1, of Annex VIII to Regulation (EC) No 999/2001 of the European Parliament and of the Council, except during the period when they were kept at a semen collection centre that complied during that period with the conditions set out in Chapter A, Section A, point 1.3(c)(iv), of Annex VIII to Regulation (EC) No 999/2001.]

(1) ○ or [they were collected from animals which have been kept continuously for the last 3 years before the collection on a holding or holdings which have complied for the last 3 years before collection with the requirements laid down in Chapter A, Section A, points 1.3(a) to (f), of Annex VIII to Regulation (EC) No 999/2001, except during the period when they were kept at a semen collection centre that complied during that period with the conditions set out in Chapter A, Section A, point 1.3(c)(iv), of Annex VIII to Regulation (EC) No 999/2001.]

(1) ○ or [they were collected from animals which have been kept continuously since birth in a Member State or zone of a Member State listed in Chapter A, Section A, point 2.3, of Annex VIII to Regulation (EC) No 999/2001 as having a negligible risk status for classical scrapie.]

(1) ○ or [they were collected from ovine animals, and:

(1) ○ either [are of the ARR/ARR prion protein genotype.]

(1) ○ or [carry at least one ARR allele.]]

II.3. The ☐ [oocytes] (1) ☐ [embryos] (1) described in Part I are intended for artificial reproduction and were obtained from donor animals which:

II.3.1. have been born and remained since birth in the Union, or have entered the Union in accordance with the requirements for entry into the Union;

II.3.2. come from establishments in a Member State or zone thereof, or from establishments under official control by the competent authority in a third country or territory, or a zone thereof:

II.3.2.1. free from infection with Brucella abortus, B. melitensis and B. suis and have never been kept previously in any establishment of a lower health status;

(1) (6) ☐ [II.3.2.2. in which infection with Mycobacterium tuberculosis complex (M. bovis, M. caprae and M. tuberculosis) has not been reported during the last 42 days prior to the date of ☐ [collection] (1) ☐ [production] (1) of the ☐ [oocytes] (1) ☐ [embryos] (1);]

(1) (7) ☐ [II.3.2.2. in which surveillance for infection with Mycobacterium tuberculosis complex (M. bovis, M. caprae and M. tuberculosis) has been carried out on the caprine animals kept in the establishments during at least 12 months prior to the date of ☐ [collection] (1) ☐ [production] (1) of the ☐ [oocytes] (1) ☐ [embryos] (1), as referred to in Article 15(3) of Commission Delegated Regulation (EU) 2020/688, and in case, during this period, infection with Mycobacterium tuberculosis complex (M. bovis, M. caprae and M. tuberculosis) has been reported in caprine animals kept in the establishment, measures were taken in

Part II: Certification

II. Health information		

accordance with Part 1, point 3, of Annex II to that Delegated Regulation;]

II.3.2.3. in which surra (Trypanosoma evansi) has not been reported during the last 30 days prior to the date of ☐ [collection] (1) ☐ [production] (1) of the ☐ [oocytes] (1) ☐ [embryos] (1), and:

(1) ○ either [surra has not been reported in the establishments during the last 2 years prior to the date of ☐ [collection] (1) ☐ [production] (1) of the ☐ [oocytes] (1) ☐ [embryos] (1);]

(1) ○ or [surra has been reported in the establishments during the last 2 years prior to the date of ☐ [collection] (1) ☐ [production] (1) of the ☐ [oocytes] (1) ☐ [embryos] (1) and following the date of the last outbreak, the affected establishments have remained under movement restrictions until the date on which the infected animals have been removed from the establishment, and the remaining animals in the establishment have been subjected to a test for surra with one of the diagnostic methods provided for in Part 3 of Annex I to Delegated Regulation (EU) 2020/688, carried out, with negative results, on samples taken during at least 6 months following the date on which the infected animals have been removed from the establishment;]

II.3.3. were examined by the team veterinarian or a team member and did not show symptoms or clinical signs of transmissible animal diseases on the date of ☐ [collection] (1) ☐ [production] (1) of the ☐ [oocytes] (1) ☐ [embryos] (1);

II.3.4. are individually identified as provided for in Article 45(2) or (4), or Article 46(1) or (3) of Commission Delegated Regulation (EU) 2019/2035;

II.3.5. for at least 30 days prior to the date of first ☐ [collection] (1) ☐ [production] (1) of the ☐ [oocytes] (1) ☐ [embryos] (1) and during the collection period:

II.3.5.1. were kept in establishments situated in a zone not subject to movement restrictions established due to the occurrence of foot and mouth disease, infection with rinderpest virus, infection with Rift Valley fever virus, infection with peste des petits ruminants virus, sheep pox and goat pox or contagious caprine pleuropneumonia, or of an emerging disease relevant for ovine and caprine animals;

II.3.5.2. were kept in a single establishment where infection with Brucella abortus, B. melitensis and B. suis, infection with Mycobacterium tuberculosis complex (M. bovis, M. caprae and M. tuberculosis), rabies, anthrax, surra (Trypanosoma evansi), infection with epizootic haemorrhagic disease virus, infection with bluetongue virus (serotypes 1-24) and, in case of ovine animals and those caprine animals which are kept together with ovine animals, ovine epididymitis (Brucella ovis) have not been reported;

II.3.5.3. were not in contact with animals from establishments situated in a zone subject to movement restrictions due to the occurrence of diseases referred to in point II.3.5.1 or from establishments which do not meet the conditions referred to in point II.3.5.2;

II.3.5.4. were not used for natural breeding;

II.3.6. comply with the following conditions as regards foot and mouth disease:

II.3.6.1. they come from establishments:

- situated in an area where foot and mouth disease has not been reported within a 10-km radius centred on the establishment for at least 30 days immediately prior to the date of collection of the ☐ [oocytes] (1) ☐ [embryos] (1);

- in which foot and mouth disease has not been reported during at least 3 months immediately prior to the date of collection of the ☐ [oocytes] (1) ☐ [embryos] (1);

(1) ○ either [II.3.6.2. they were not vaccinated against foot and mouth disease;]

(1) (5) ○ or [II.3.6.2. they were vaccinated against foot and mouth disease during 12 months prior to the date of collection or production of the embryos and:

II.3.6.2.1. have not been vaccinated against foot and mouth disease within at least 30 days immediately prior to the date of collection of the embryos;

II.3.6.2.2. the semen used for fertilisation was collected from a male donor that complies with the conditions set out in Part 5, Chapter I, point 1(b), of Annex II to Delegated Regulation (EU) 2020/686 or the semen complies with the conditions set out in Part 5, Chapter I, point 2, of Annex II to Delegated Regulation (EU) 2020/686;

II.3.6.2.3. prior to the date of freezing, the embryos have been subjected to trypsin washing carried out in accordance with the recommendations of the IETS Manual (6);

Part II: Certification

II. Health information

II.3.6.2.4. the embryos were stored deep frozen for at least 30 days from the date of collection, and during this period the donor animals have not shown clinical signs of foot and mouth disease;]

II.3.7. comply with at least one of the following conditions as regards infection with bluetongue virus (serotypes 1-24):

(1) ○ either [II.3.7.1. they have been kept for at least 60 days prior to the date and during the period of collection of the ☐ [oocytes] (1) ☐ [embryos] (1) in a Member State or zone thereof free from infection with bluetongue virus (serotypes 1-24) where no case of infection with bluetongue virus (serotypes 1-24) has been confirmed in the targeted animal population during the preceeding 24 months;]

(1) ○ or [II.3.7.2. they have been kept in a seasonally disease-free zone, during the seasonally disease-free period, for at least 60 days prior to the date and during the period of collection of the ☐ [oocytes] (1) ☐ [embryos] (1), in a Member State or zone thereof with an approved eradication programme against infection with bluetongue virus (serotypes 1-24);]

(1) ○ or [II.3.7.3. they have been kept in a seasonally disease-free zone, during the seasonally disease-free period, for at least 60 days prior to the date and during the period of collection of the ☐ [oocytes] (1) ☐ [embryos] (1), in a Member State or zone thereof where the competent authority of the place of origin of the consignment of ☐ [oocytes] (1) ☐ [embryos] (1) has obtained the prior written consent of the competent authority of the Member State of destination to the conditions for establishment of that seasonally disease-free zone and to accept the consignment of ☐ [oocytes] (1) ☐ [embryos] (1);]

(1) ☐ and/or [II.3.7.4. they have been kept in a vector protected establishment for at least 60 days prior to the date and during the period of collection of the ☐ [oocytes] (1) ☐ [embryos] (1);]

(1) ☐ and/or [II.3.7.5. they have been subjected to a serological test to detect antibodies to the bluetongue virus serotypes 1-24, with negative results, between 28 and 60 days from the date of each collection of the ☐ [oocytes] (1) ☐ [embryos] (1);]

(1) ☐ and/or [II.3.7.6. they have been subjected to an agent identification test for bluetongue virus (serotypes 1-24), with negative results, on blood sample taken on the day of collection of the ☐ [oocytes] (1) ☐ [embryos] (1);]

II.3.8. comply with at least one of the following conditions as regards infection with epizootic haemorrhagic disease virus (EHDV):

(1) ○ either [II.3.8.1. they have been kept for at least 60 days prior to the date and during the period of collection of the ☐ [oocytes] (1) ☐ [embryos] (1) in a Member State or zone thereof where EHDV has not been reported within a radius of 150 km of the establishment for at least 2 years;]

(1) ○ or [II.3.8.2. they have been kept in a seasonally disease-free zone, during the seasonally disease-free period, for at least 60 days prior to the date and during the period of collection of the ☐ [oocytes] (1) ☐ [embryos] (1);]

(1) ☐ and/or [II.3.8.3. they have been kept in a vector protected establishment for at least 60 days prior to the date and during the period of collection of the ☐ [oocytes] (1) ☐ [embryos] (1);]

(1) ○ or [II.3.8.4. were resident in a Member State or zone thereof in which according to official findings the following serotypes of EHDV exist: and have been subjected with negative results in each case to the following tests carried out in an official laboratory:

(1) ☐ either [II.3.8.4.1. a serological test to detect antibodies to EHDV, with negative results, on blood sample taken between 28 and 60 days from the date of the collection of the ☐ [oocytes] (1) ☐ [embryos] (1);]]

(1) ☐ and/or [II.3.8.4.2. an agent identification test for EHDV, with negative results, on blood sample taken on the date of collection of the ☐ [oocytes] (1) ☐ [embryos] (1).]]

II.4. The ☐ [oocytes] (1) ☐ [embryos] (1) described in Part I:

II.4.1. have been collected, processed and stored in accordance with animal health requirements set out in ☐ [Part 2] (1) ☐ [Part 3] (1) ☐ [Part 4] (1) ☐ [Part 5] (1) and Part 6 of Annex III to Delegated Regulation (EU) 2020/686;

II.4.2. are placed in straws or other packages on which the mark is applied in accordance with requirements provided for in Article 10 of Delegated Regulation (EU) 2020/686 and that mark is indicated in box I.30;

II.4.3. are transported in a container which:

Part II: Certification

II. Health information		

II.4.3.1. was sealed and numbered prior to the date of dispatch by the embryo collection or production team under responsibility of the team veterinarian, or by an official veterinarian, and the seal bears the number as indicated in box I.19;

II.4.3.2. has been cleaned and either disinfected or sterilised before use, or is single-use container;

(1)(7) ☐ [II.4.3.3. has been filled in with a cryogenic agent which has not been previously used for other products;]

(1)(8) ☐ [II.4.4. are placed in straws or other packages which are securely and hermetically sealed;

II.4.5. are transported in a container where the different types are separated from each other by physical compartments or by being placed in secondary protective bags.]

(1) (9) ☐ [II.5. The ☐ [in vivo derived embryos] (1) ☐ [in vitro produced embryos] (1) ☐ [micromanipulated embryos] (1) described in Part I were conceived by artificial insemination using semen coming from a semen collection centre, germinal product processing establishment or germinal product storage centre approved for the collection, processing and/or storage of semen by the competent authority of a Member State or by the competent authority of a third country or territory, or zone thereof listed in Annex X to Commission Implementing Regulation (EU) 2021/404, and which was collected, processed and stored in accordance with the requirements of Part 3, Chapter I, and Part 5, Chapters II and III, of Annex II, and of Part 1 of Annex III to Delegated Regulation (EU) 2020/686.]

(1)(10) ☐ [II.6. The following antibiotic or mixture of antibiotics (11) has been added to the collection, processing, washing or storage media:]

II.7. The ☐ [oocytes] (1) ☐ [embryos] (1) described in Part I are dispatched by:

(1) ○ either [an ☐ [embryo collection team] (1) ☐ [embryo production team] (1) or from a zone not subject to movement restrictions affecting ovine and caprine animals and established for reasons of listed diseases relevant for those species or diseases subject to emergency measures relevant for those species or those restrictions do not apply to these oocytes or embryos because they were collected before the restrictions were established, and they have not been in contact with other oocytes or embryos of a lower health status for an adequate period.]

(1) ○ or [an ☐ [embryo collection team] (1) ☐ [embryo production team] (1) or from a zone subject to movement restrictions affecting ovine and caprine animals and established for (12), but derogations from movement restrictions have been granted, and:

(1) ☐ [they comply with the requirements set out in (13);]]

(1) ☐ [and, in particular, they are (14).]]

Notes:

In accordance with the Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community, and in particular Article 5(4) of the Protocol on Ireland/Northern Ireland in conjunction with Annex 2 to that Protocol, references to the Union in this animal health certificate include the United Kingdom in respect of Northern Ireland.

This animal health certificate shall be completed in accordance with the notes for the completion of certificates provided for in Chapter 2 of Annex I to Commission Implementing Regulation (EU) 2020/2235.

Part I:

Box reference I.11: “Place of dispatch”: Indicate the unique approval number and the name and address of the embryo collection or production team of dispatch of the consignment of oocytes or embryos.

Box reference I.12: “Place of destination”: Indicate the address and unique registration or approval number of the establishment of destination of the consignment of oocytes or embryos.

Box reference I.19: Seal number shall be indicated.

Box reference I.26: Total number of packages shall correspond to the number of containers.

Part II: Certification

II. Health information		

Box reference I.30: “Type”: Specify if in vivo derived embryos, in vivo derived oocytes, in vitro produced embryos or micromanipulated embryos.

“Species”: Select amongst “Ovis aries” or “Capra hircus” as appropriate.

“Identification number”: Indicate the identification number of each donor animal.

“Identification mark”: Indicate the mark on the straw or other packages where the oocytes or embryos of the consignment are placed.

“Date of collection/production”: Indicate the date on which the oocytes or embryos of the consignment were collected or produced.

“Approval or registration number of plant/establishment/centre”: Indicate the unique approval number of the embryo collection or production team by which the the oocytes or embryos of the consignment were collected or produced.

“Quantity”: Indicate the number of straws or other packages with the same mark.

“Test”: Indicate for BTV-test: point II.3.7.5 and/or point II.3.7.6, and/or for EHD-test: point II.3.8.4.1 and/or point II.3.8.4.2, if relevant.

Part II:

(1) Delete if not applicable.

(2) Only embryo collection or production teams approved by the competent authority and included in the register referred to in Article 101(1), point (b,) of Regulation (EU) 2016/429 of the European Parliament and of the Council and Article 7 of Delegated Regulation (EU) 2020/686.

(3) Applicable for ovine animals.

(4) Applicable for caprine animals.

(5) Option available only for consignments of in vivo derived embryos.

(6) Manual of the International Embryo Technology Society — A procedural guide and general information for the use of embryo transfer technology emphasising sanitary procedures, published by the International Embryo Technology Society, 1 111 North Dunlap Avenue, Savoy, Illinois 61 874, USA (http://www.iets.org/).

(7) Applicable for frozen oocytes or embryos.

(8) Applicable for consignments where oocytes, in vivo derived embryos, in vitro produced embryos and micromanipulated embryos of ovine or caprine animals are placed and transported in one container.

(9) Does not apply to oocytes.

(10) Mandatory attestation in case antibiotic(s) was/were added.

(11) Insert the name(s) of the antibiotic(s) added and its (their) concentration.

(12) Insert the name of the disease(s).

(13) Insert the specific reference to the article(s), title, and number of the relevant legal act(s) adopted by the Commission providing for those requirements.

(14) Insert the specific attestation(s) provided for in and required by the relevant legal act(s) adopted by the Commission, as referred to in Article 159(2), points (a), (b) and (c), of Regulation (EU) 2016/429.

Certifying Officer/Official veterinarian	
Name (in capital letters)	Qualification and title
Date of declaration	Signature
Stamp	